3q21q26 rearrangements in treatment related leukemia by Huret, JL









Atlas Genet Cytogenet Oncol Haematol. 2005; 9(3)  
 
234 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
3q21q26 rearrangements in treatment related 
leukemia 
Jean-Loup Huret 
Genetics, Dept Medical Information, UMR 8125 CNRS, University of Poitiers, CHU Poitiers Hospital, F-
86021 Poitiers, France (JLH) 
 
Published in Atlas Database: May 2005 
Online updated version: http://AtlasGeneticsOncology.org/Anomalies/3q21q26TreatRelLeukID1236.html 
DOI: 10.4267/2042/38214 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 




This data is extracted from a very large study from an 
International Workshop on treatment related 
leukemias-restricted to balanced chromosome 
aberrations (i.e.: -5/del(5q)and -7/del(7q) not taken into 
account per see), published in Genes, Chromosomes 
and Cancer in 2002. 
Clinics and pathology 
Disease 
Treatment related myelodysplasia (t-MDS) or acute 
non lymphocytic leukaemias (t-ANLL). 
Note: The study included 17 cases; t-MDS without 
progression to ANLL accounted for 18%, t-MDS with 
progression to ANLL for 18% and t-ANLL for the 
remaining 64% (M2 or M4 mainly); no case of acute 
lymphoblastic leukaemia. 
Epidemiology 
3q21q26 rearrangements were found in 3% of t-MDS/t-
ANLL; sex ratio: 4M/13F. 
Clinics 
Age at diagnosis of the primary disease 40 yrs (range 
18-69); age at diagnosis of the t-MDS/t-ANLL: 51 yrs 
(range 22-80). Median interval was 104 mths (range: 
48-217). Primary disease was a solid tumor in 47% of 
cases and a hematologic malignancy in 53% (Hodgkin 
disease and non Hodgkin lymphoma in particular), 
treatment was chemotherapy (18%), radiotherapy 
(29%), or both chemotherapy and radiotherapy (53%).  
Chemotherapy included topoisomerase II inhibitors in 
42% of cases and alkylating agents in 100%. 
Prognosis 
Median survival was 7 mths, with 30% of patients 
surviving at 1 yr, and 20% at 2 yrs. 
Cytogenetics 
Additional anomalies 
3q21q26 rearrangements included inv(3)(q21q26) in 
71% of cases, t(3;3)(q21q26)in 23%, and 
ins(3)(q26;q21q26) in 1 case (6%); additional 
anomalies were: -7/del(7q) in 82%, -5/del(5q) in 35 %, 
del(6q) and del(20q) in 12 % each. Complex 
karyotypes were found in 53%. 




RPN1 (ribophorin 1) 
Location 
3q21 




RPN1enhancer juxtaposed to EVI1. 
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